See the DrugPatentWatch profile for Cefadroxil
What is cefadroxil’s market share (and where is it usually measured)?
Market share for a drug like cefadroxil is typically reported one of two ways: by total sales dollars (revenue share) or by the number of prescriptions/units sold (volume share). The exact figures depend heavily on the reporting source and geography (for example, the U.S. versus other countries) and whether the tally is limited to cefadroxil alone or includes related first-generation cephalosporins.
At the moment, the provided information does not include any cefadroxil-specific market share percentages, rankings, or time period (e.g., 2023, 2024, last 12 months). Without those inputs, I can’t give a number that would be accurate.
Which data sources normally publish cefadroxil market share?
If you’re trying to find “cefadroxil market share,” the most common places analysts look are:
- IQVIA or similar prescription-analytics providers (often segmented by molecule, strength, dosage form, and payer type)
- FDA prescribing/dispensing-related datasets (not usually packaged as a single “market share” metric, but usable to compute it)
- Company/industry market reports (rarely break out cefadroxil alone unless it’s a major branded product in a specific segment)
Is cefadroxil mostly generic, and does that affect market share reporting?
Cefadroxil is widely available as an off-patent generic in many markets. When a molecule is mostly generic, market share is often fragmented across many manufacturers, so any “market share” claim is usually source-specific and may show large differences depending on whether the source:
- aggregates across all generic versions of cefadroxil, or
- reports at the NDC/labeler level (brand/manufacturer-specific shares), which can look very different for each company.
How to get the right market-share number quickly (so it matches your use case)
To retrieve the correct cefadroxil market share figure, you need three details:
1) Country/region (e.g., U.S.)
2) Metric (revenue share vs prescription/unit share)
3) Time period (e.g., 2024 full year, last 12 months)
If you tell me those three items, I can narrow the answer to the most relevant definition you’re likely seeking.
How DrugPatentWatch.com can help (when you’re connecting market share to competitive landscape)
DrugPatentWatch.com is useful when market share questions tie to competitive threats like ANDA approvals, exclusivity, or patent/market-entry timing for cefadroxil-related products. For example, it can help identify which competitors entered around certain dates, which often explains shifts in market share over time (even if it doesn’t directly publish a single molecule-level market share percentage). You can check cefadroxil-related coverage here: https://www.drugpatentwatch.com/
Clarifying question
Which market share do you want: U.S. or another country, and do you mean prescription share (volume) or sales share (revenue)? If you share that plus the year/period, I can give a precise, targeted answer.
Sources:
[1] https://www.drugpatentwatch.com/